Distinctive mesenchymal-like neurofibroma stem cells shape NF1 clinical phenotypes controlled by BDNF...

Area of Science:

• Oncology
• Stem Cell Biology
• Genetics

Background:

• Neurofibroma type I (NF1) is characterized by diverse clinical presentations stemming from NF1 gene mutations.
• The tumor microenvironment's role in NF1 pathogenesis is not fully understood.
• Investigating tumor stem cells and their microenvironment is crucial for NF1 management.

Purpose of the Study:

• To identify and characterize a novel subgroup of stem cells within NF1 tumors.
• To explore the phenotypic and therapeutic relevance of the tumor microenvironment in NF1.
• To elucidate the role of brain-derived neurotrophic factor (BDNF) in NF1 tumor development.

Main Methods:

• Isolation and culture of tumor stem cells (TSCs) from NF1 patients.
• Flow cytometry, differentiation assays, and in vivo tumorigenesis studies to characterize TSCs.
• Immunohistochemistry, ELISA, and Western Blotting to analyze BDNF expression and signaling pathways (TrkB/p38 MAPK).

Main Results:

• Identification of mesenchymal-like neurofibroma stem cells (MNSCs) with self-renewal, differentiation, and tumorigenic potential.
• Demonstration of site-specific capabilities of MNSCs from different tumor locations within the same patient.
• Evidence that BDNF activates the TrkB/p38 MAPK pathway in MNSCs, influencing tumor phenotypes.

Conclusions:

• BDNF modulates MNSCs, controlling tumor phenotypes in NF1, particularly between head and trunk regions.
• BDNF neutralizing antibodies inhibit MNSCs and the p38 MAPK pathway.
• BDNF-targeted therapies represent a promising strategy for managing NF1.